Drug Profile
Research programme: cardiology, oncology, haematology, gynaecology and ophthalmology therapeutics - Bayer/Kyoto University
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Bayer; Kyoto University
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Eye disorders; Female genital diseases; Haematological disorders
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Cancer in Japan
- 28 Nov 2018 No recent reports of development identified for research development in Cardiovascular-disorders in Japan
- 28 Nov 2018 No recent reports of development identified for research development in Eye-disorders in Japan